Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme - LARVOL DELTA

PET-Directed Colonoscopy Revealing Follicular Lymphoma Involving a Rectal Villous Adenoma in a Patient With Systemic Follicular Lymphoma (ACG 2026) - "Maintenance subcutaneous rituximab was initiated...This case highlights the importance of investigating PET-positive colorectal lesions in patients with known lymphoma and emphasizes that endoscopically benign-appearing polyps may represent multifocal gastrointestinal FL. Figure: Imaging and Colonoscopy Figure: Histological examination"

Clinical • Colorectal Cancer • Diabetes • Follicular Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Hepatitis B • Hepatology • Indolent Lymphoma • Infectious Disease • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Type 2 Diabetes Mellitus • BCL2 • BCL6 • CCND1 • CD20 • CD5 • MME

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update (ASH 2022) - P1b/2 | "All CRS events resolved (median time to resolution, 2 d; range, 1–4), no patients discontinued treatment due to CRS, and 5 patients received tocilizumab. In patients with R/R FL, subcutaneous epcoritamab + R2 demonstrated a manageable safety profile with only low-grade CRS events, mostly observed following the first full dose and all of which resolved. No new safety signals were detected. Data from this cohort are very encouraging with a high CMR rate observed in patients with R/R FL."

Clinical • P1/2 data • Fatigue • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • CD20

From haematology to rheumatology: intravenous-to-subcutaneous rituximab transition in Sjögren disease-associated cryoglobulinaemic vasculitis. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • Hematological Disorders • Rheumatology • Sjogren's Syndrome • Vasculitis

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. (PubMed, J Clin Oncol) - "SC rituximab improves PFS for patients with low-tumor burden FL when used in induction followed by short maintenance. High rituximab exposure during the first 3 months after treatment initiation is, however, the only parameter influencing patient outcomes."

Journal • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma (clinicaltrials.gov) - P2/3 | N=271 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P2/3 trial • B Cell Lymphoma • Burkitt Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

CARiBOU: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - P2 | N=41 | Active, not recruiting | Sponsor: Academic and Community Cancer Research United | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2024 ➔ Aug 2025

Enrollment closed • Trial primary completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=33 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2027 ➔ Jan 2027

Enrollment closed • Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov) - P3 | N=102 | Not yet recruiting | Sponsor: SWOG Cancer Research Network | Initiation date: May 2026 ➔ Aug 2026

Trial initiation date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma

IELSG38: THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS WITH A TYPE OF LYMPHOMA CALLED MALT LYMPHOMA (clinicaltrialsregister.eu) - P1/2 | N=106 | Completed | Sponsor: Association International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting ➔ Completed

Trial completion • B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Canadian Cancer Trials Group | Recruiting ➔ Active, not recruiting | N=18 ➔ 40

Enrollment change • Enrollment closed • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P2/3 | N=422 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Breast Cancer • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • T Cell Histiocyte Rich Large B Cell Lymphoma • Waldenstrom Macroglobulinemia • BCL2 • BCL6 • CD4

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=5 | Terminated | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial completion date: Nov 2026 ➔ Oct 2025 | Active, not recruiting ➔ Terminated; Funding

Trial completion date • Trial termination • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Initiation date: Jun 2019 ➔ Sep 2019

Trial initiation date • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Oncology • Splenic Marginal Zone Lymphoma • CD20

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (clinicaltrials.gov) - P2 | N=175 | Active, not recruiting | Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Recruiting ➔ Active, not recruiting

Enrollment closed • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Oncology • Splenic Marginal Zone Lymphoma • CD20

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (clinicaltrials.gov) - P2 | N=175 | Active, not recruiting | Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Trial primary completion date: Jun 2024 ➔ Jun 2027

Trial primary completion date • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Oncology • Splenic Marginal Zone Lymphoma • CD20

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: International Extranodal Lymphoma Study Group (IELSG)

New P2 trial • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Splenic Marginal Zone Lymphoma • CD20

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Not yet recruiting ➔ Recruiting

Enrollment open • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Oncology • Splenic Marginal Zone Lymphoma • CD20

ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov) - P3 | N=546 | Not yet recruiting | Sponsor: Acerta Pharma BV

New P3 trial • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1 • CD20 • CD5 • PAX5

ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov) - P3 | N=635 | Active, not recruiting | Sponsor: Acerta Pharma BV | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2024 ➔ Oct 2025 | Trial primary completion date: Apr 2023 ➔ Oct 2025

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1 • CD20 • CD5 • PAX5

ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov) - P3 | N=546 | Recruiting | Sponsor: Acerta Pharma BV | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1 • CD20 • CD5 • PAX5

ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov) - P3 | N=546 | Recruiting | Sponsor: Acerta Pharma BV | Trial completion date: Apr 2023 ➔ Nov 2022

Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1 • CD20 • CD5 • PAX5

ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov) - P3 | N=546 | Recruiting | Sponsor: Acerta Pharma BV | Trial completion date: Apr 2023 ➔ Feb 2024

Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1 • CD20 • CD5 • PAX5

ACE-LY-308: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (clinicaltrials.gov) - P3 | N=635 | Active, not recruiting | Sponsor: Acerta Pharma BV | Trial completion date: Oct 2025 ➔ Feb 2027 | Trial primary completion date: Oct 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CCND1 • CD20 • CD5 • PAX5

CCTG LY18-A: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Canadian Cancer Trials Group | Trial completion date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: Georgetown University | Trial completion date: Jan 2026 ➔ Dec 2026 | Trial primary completion date: Oct 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology